vs
MARCUS CORP（MCS）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是MARCUS CORP的1.9倍（$373.9M vs $193.5M），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 2.8%），MARCUS CORP自由现金流更多（$26.4M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 18.2%）
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
MCS vs PAHC — 直观对比
营收规模更大
PAHC
是对方的1.9倍
$193.5M
营收增速更快
PAHC
高出18.2%
2.8%
自由现金流更多
MCS
多$18.1M
$8.3M
两年增速更快
PAHC
近两年复合增速
18.2%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $193.5M | $373.9M |
| 净利润 | — | $27.5M |
| 毛利率 | — | 35.5% |
| 营业利润率 | 0.9% | 13.5% |
| 净利率 | — | 7.3% |
| 营收同比 | 2.8% | 20.9% |
| 净利润同比 | — | 762.1% |
| 每股收益（稀释后） | — | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MCSPAHC
| Q4 25 | $193.5M | $373.9M | ||
| Q3 25 | $210.2M | $363.9M | ||
| Q2 25 | $206.0M | $378.7M | ||
| Q1 25 | $148.8M | $347.8M | ||
| Q4 24 | $188.3M | $309.3M | ||
| Q3 24 | $232.7M | $260.4M | ||
| Q2 24 | $176.0M | $273.2M | ||
| Q1 24 | $138.5M | $263.2M |
净利润MCSPAHC
| Q4 25 | — | $27.5M | ||
| Q3 25 | $16.2M | $26.5M | ||
| Q2 25 | $7.3M | $17.2M | ||
| Q1 25 | $-16.8M | $20.9M | ||
| Q4 24 | $986.0K | $3.2M | ||
| Q3 24 | $23.3M | $7.0M | ||
| Q2 24 | $-20.2M | $752.0K | ||
| Q1 24 | $-11.9M | $8.4M |
毛利率MCSPAHC
| Q4 25 | — | 35.5% | ||
| Q3 25 | — | 32.9% | ||
| Q2 25 | — | 29.0% | ||
| Q1 25 | — | 30.1% | ||
| Q4 24 | — | 32.9% | ||
| Q3 24 | — | 32.1% | ||
| Q2 24 | — | 31.9% | ||
| Q1 24 | — | 30.2% |
营业利润率MCSPAHC
| Q4 25 | 0.9% | 13.5% | ||
| Q3 25 | 10.8% | 14.1% | ||
| Q2 25 | 6.3% | 8.9% | ||
| Q1 25 | -13.7% | 9.6% | ||
| Q4 24 | -1.2% | 8.3% | ||
| Q3 24 | 14.1% | 6.8% | ||
| Q2 24 | 1.3% | 6.7% | ||
| Q1 24 | -12.0% | 7.6% |
净利率MCSPAHC
| Q4 25 | — | 7.3% | ||
| Q3 25 | 7.7% | 7.3% | ||
| Q2 25 | 3.6% | 4.5% | ||
| Q1 25 | -11.3% | 6.0% | ||
| Q4 24 | 0.5% | 1.0% | ||
| Q3 24 | 10.0% | 2.7% | ||
| Q2 24 | -11.5% | 0.3% | ||
| Q1 24 | -8.6% | 3.2% |
每股收益（稀释后）MCSPAHC
| Q4 25 | — | $0.67 | ||
| Q3 25 | — | $0.65 | ||
| Q2 25 | — | $0.43 | ||
| Q1 25 | — | $0.51 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | — | $0.17 | ||
| Q2 24 | — | $0.02 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.4M | $74.5M |
| 总债务越低越好 | $159.0M | $624.2M |
| 股东权益账面价值 | $457.4M | $332.4M |
| 总资产 | $1.0B | $1.4B |
| 负债/权益比越低杠杆越低 | 0.35× | 1.88× |
8季度趋势，按日历期对齐
现金及短期投资MCSPAHC
| Q4 25 | $23.4M | $74.5M | ||
| Q3 25 | $7.4M | $85.3M | ||
| Q2 25 | $14.9M | $77.0M | ||
| Q1 25 | $11.9M | $70.4M | ||
| Q4 24 | $40.8M | $67.1M | ||
| Q3 24 | $28.4M | $89.8M | ||
| Q2 24 | $32.8M | $114.6M | ||
| Q1 24 | $17.3M | $98.7M |
总债务MCSPAHC
| Q4 25 | $159.0M | $624.2M | ||
| Q3 25 | $162.0M | $628.0M | ||
| Q2 25 | $179.9M | $631.7M | ||
| Q1 25 | $198.9M | $635.4M | ||
| Q4 24 | $159.1M | $639.1M | ||
| Q3 24 | $173.1M | $295.2M | ||
| Q2 24 | $175.7M | $312.1M | ||
| Q1 24 | $169.8M | — |
股东权益MCSPAHC
| Q4 25 | $457.4M | $332.4M | ||
| Q3 25 | $454.3M | $311.7M | ||
| Q2 25 | $448.4M | $285.7M | ||
| Q1 25 | $441.8M | $266.0M | ||
| Q4 24 | $464.9M | $246.8M | ||
| Q3 24 | $462.3M | $258.5M | ||
| Q2 24 | $449.4M | $256.6M | ||
| Q1 24 | $459.3M | $270.1M |
总资产MCSPAHC
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.0B | $1.3B | ||
| Q3 24 | $1.0B | $966.3M | ||
| Q2 24 | $1.1B | $982.2M | ||
| Q1 24 | $1.0B | $979.0M |
负债/权益比MCSPAHC
| Q4 25 | 0.35× | 1.88× | ||
| Q3 25 | 0.36× | 2.01× | ||
| Q2 25 | 0.40× | 2.21× | ||
| Q1 25 | 0.45× | 2.39× | ||
| Q4 24 | 0.34× | 2.59× | ||
| Q3 24 | 0.37× | 1.14× | ||
| Q2 24 | 0.39× | 1.22× | ||
| Q1 24 | 0.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.8M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $26.4M | $8.3M |
| 自由现金流率自由现金流/营收 | 13.6% | 2.2% |
| 资本支出强度资本支出/营收 | 11.6% | 3.0% |
| 现金转化率经营现金流/净利润 | — | 0.70× |
| 过去12个月自由现金流最近4个季度 | $989.0K | $47.3M |
8季度趋势，按日历期对齐
经营现金流MCSPAHC
| Q4 25 | $48.8M | $19.4M | ||
| Q3 25 | $39.1M | $9.3M | ||
| Q2 25 | $31.6M | $21.3M | ||
| Q1 25 | $-35.3M | $43.2M | ||
| Q4 24 | $52.6M | $3.1M | ||
| Q3 24 | $30.5M | $12.6M | ||
| Q2 24 | $36.0M | $28.4M | ||
| Q1 24 | $-15.1M | $11.4M |
自由现金流MCSPAHC
| Q4 25 | $26.4M | $8.3M | ||
| Q3 25 | $18.2M | $-4.5M | ||
| Q2 25 | $14.7M | $8.1M | ||
| Q1 25 | $-58.3M | $35.4M | ||
| Q4 24 | $27.1M | $-4.7M | ||
| Q3 24 | $12.0M | $3.0M | ||
| Q2 24 | $16.1M | $15.4M | ||
| Q1 24 | $-30.5M | $1.7M |
自由现金流率MCSPAHC
| Q4 25 | 13.6% | 2.2% | ||
| Q3 25 | 8.7% | -1.2% | ||
| Q2 25 | 7.1% | 2.1% | ||
| Q1 25 | -39.2% | 10.2% | ||
| Q4 24 | 14.4% | -1.5% | ||
| Q3 24 | 5.2% | 1.2% | ||
| Q2 24 | 9.2% | 5.6% | ||
| Q1 24 | -22.0% | 0.6% |
资本支出强度MCSPAHC
| Q4 25 | 11.6% | 3.0% | ||
| Q3 25 | 9.9% | 3.8% | ||
| Q2 25 | 8.2% | 3.5% | ||
| Q1 25 | 15.5% | 2.2% | ||
| Q4 24 | 13.5% | 2.5% | ||
| Q3 24 | 7.9% | 3.7% | ||
| Q2 24 | 11.3% | 4.8% | ||
| Q1 24 | 11.1% | 3.7% |
现金转化率MCSPAHC
| Q4 25 | — | 0.70× | ||
| Q3 25 | 2.41× | 0.35× | ||
| Q2 25 | 4.32× | 1.24× | ||
| Q1 25 | — | 2.07× | ||
| Q4 24 | 53.31× | 0.97× | ||
| Q3 24 | 1.31× | 1.81× | ||
| Q2 24 | — | 37.80× | ||
| Q1 24 | — | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
